Your browser doesn't support javascript.
loading
BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
Ribero, Simone; Malavenda, Ottavia; Fava, Paolo; Astrua, Chiara; Marra, Elena; Osella-Abate, Simona; Sanlorenzo, Martina; Caliendo, Virginia; Fierro, Maria Teresa; Quaglino, Pietro.
Affiliation
  • Ribero S; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Malavenda O; Faculty of Medicine, University of Turin, Turin, Italy.
  • Fava P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Astrua C; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Marra E; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Osella-Abate S; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Sanlorenzo M; Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Caliendo V; Department of Oncology, Section of Dermatologic Surgery, University Hospital Citta della Scienza e della Salute di Torino, Turin, Italy.
  • Fierro MT; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Quaglino P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
Future Oncol ; 15(2): 133-139, 2019 Jan.
Article in En | MEDLINE | ID: mdl-30196713
ABSTRACT

AIM:

A survival benefit was demonstrated by dabrafenib + trametinib for metastatic BRAF-mutated melanoma patients. Best response is a strong prognostic marker for survival. PATIENTS &

METHODS:

The specific features associated with complete response (CR) were evaluated.

RESULTS:

A total of 15/66 patients achieved CR. Median size of lesions was 3 cm (range 0.5-10). Using that value as cut-off, the CR rate was 39.3% in patients with smaller lesions and 10.5% in patients with bigger size (p = 0.006). The clinical features associated with CR were the number of metastatic sites and the largest diameter of the biggest metastatic site.

CONCLUSION:

The number of the metastases and the diameter of the largest metastatic site are associated with a higher CR rate.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / Melanoma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 Language: En Journal: Future Oncol Year: 2019 Type: Article Affiliation country: Italy
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / Melanoma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 Language: En Journal: Future Oncol Year: 2019 Type: Article Affiliation country: Italy